<DOC>
	<DOCNO>NCT00918450</DOCNO>
	<brief_summary>This Phase 2b , open-label , multicenter , global study assess safety efficacy ABT-263 subject B-cell CLL fail least one prior fludarabine-containing regimen .</brief_summary>
	<brief_title>Study Assessing Safety Efficacy ABT-263 Subjects With B-cell Chronic Lymphocytic Leukemia ( CLL ) Who Have Failed Least One Prior Fludarabine-containing Regimen</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<criteria>&gt; = 18 yr age , Bcell CLL , fail least 1 prior fludarabinecontaining regimen . Refractory 1 fludarabinecontaining regimen define failure achieve least PR last fludarabinecontaining regimen receive , disease progression receive last fludarabinecontaining regimen , disease progression responder ( i.e. , achieve PR CR ) within 6 mo last cycle last fludarabinecontaining regimen receive ( e.g. , fludarabine monotherapy , FR , FC ) responder ( i.e. , achieve PR CR ) within 24 mo last cycle FCR . Intolerant fludarabine define discontinuation therapy within 2 cycle due side effects/toxicity last fludarabinecontaining regimen . ECOG score &lt; =1 . Adequate coagulation , renal , &amp; hepatic function Screening follow : Serum creatinine &lt; = 2.0 mg/dL calculate creatinine clearance &gt; = 50 mL/min ; AST &amp; ALT &lt; = 3.0 x ULN ; Bilirubin &lt; = 1.5 x ULN . Gilbert 's Syndrome may Bilirubin &gt; 1.5 x ULN ; aPTT , PT , exceed 1.2 x ULN . Adequate bone marrow ( BM ) independent growth factor support ( exception subject BM heavily infiltrate underlying disease [ 80 % ] may use growth factor support achieve adequate BM ) Screening follow : ANC &gt; = 1000/µL ; Platelets &gt; = 75,000/mm3 ( entry platelet count must independent transfusion within 14 day Screening ) ; Hemoglobin &gt; = 9.0 g/dL . History autologous BM transplant must &gt; 6 mo post transplant ( prior 1st dose study drug ) &amp; adequate BM independent growth factor support ( exception subject BM heavily infiltrate underlying disease [ 80 % ] may use growth factor support achieve adequate BM ) Screening follow : ANC &gt; = 1500/µL ; Platelets &gt; = 125,000/mm3 ; Hemoglobin &gt; = 10.0 g/dL . Female subject must surgically sterile , postmenopausal ( least 1 year ) , negative result pregnancy test . All female subject surgically sterile postmenopausal ( least 1 year ) &amp; nonvasectomized male subject must practice birth control . History/clinically suspicious cancerrelated CNS disease . Undergone allogeneic stem cell transplant . Undergone autologous stem cell transplant w/i 6 mo prior 1st dose . History/predisposing condition bleed currently exhibit sign bleed . Recent history nonchemotherapy induce thrombocytopenic associate bleed w/i 6 mo prior 1st dose . Active peptic ulcer disease hemorrhagic esophagitis/gastritis . Active immune thrombocytopenic purpura history refractory platelet transfusion w/i 1 yr prior 1st dose . Currently receiving/requires anticoagulation therapy drug herbal supplement affect platelet function , exception lowdose anticoagulation medication use maintain patency central IV catheter . Significant history cardiovascular disease , renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , hepatic disease . Positive HIV , Hepatitis B , Hepatitis C. Previous current malignancy w/i last 3 yr : except adequately treat situ carcinoma cervix uterus ; basal squamous cell carcinoma ; situ carcinoma bladder ; previous malignancy confine surgically resect curative intent . Has Prolymphocytic leukemia Richter 's transformation aggressive Bcell malignancy . Exhibits evidence clinically significant uncontrolled condition ( ) include , limited uncontrolled systemic infection diagnosis fever neutropenia w/i 1 week prior study drug . Prior exposure ABT263 . Received antibody therapy w/i 30 day prior 1st dose . Received anticancer therapy include chemotherapy , immunotherapy , radiotherapy , hormonal , investigational therapy w/i 14 day prior 1st dose , recover &lt; Gr2 clinically significant AE ( ) /toxicity ( ) previous therapy . Received steroid therapy antineoplastic intent , w/i 7 day prior 1st dose exception inhale steroid asthma , topical steroid , replacement/stress corticosteroid . Received aspirin w/i 7 day prior 1st dose . Consumed grapefruit grapefruit product w/i 3 day prior 1st dose . Females pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>